SENS icon

Senseonics Holdings

0.5999 USD
+0.0058
0.98%
At close Apr 17, 4:00 PM EDT
After hours
0.6000
+0.0001
0.02%
1 day
0.98%
5 days
1.68%
1 month
-3.05%
3 months
-29.25%
6 months
71.40%
Year to date
26.80%
1 year
49.15%
5 years
-13.06%
10 years
-78.95%
 

About: Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Employees: 117

0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

101% more capital invested

Capital invested by funds: $20.8M [Q3] → $41.8M (+$21M) [Q4]

98% more call options, than puts

Call options by funds: $324K | Put options by funds: $164K

56% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 18

2.34% more ownership

Funds ownership: 11.08% [Q3] → 13.41% (+2.34%) [Q4]

8% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 24

5% less funds holding

Funds holding: 129 [Q3] → 123 (-6) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$2
233%
upside
Avg. target
$2
233%
upside
High target
$2
233%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Mizuho
Anthony Petrone
45% 1-year accuracy
10 / 22 met price target
233%upside
$2
Outperform
Initiated
10 Apr 2025
HC Wainwright & Co.
Vernon Bernardino
18% 1-year accuracy
13 / 71 met price target
233%upside
$2
Buy
Reiterated
5 Mar 2025

Financial journalist opinion

Positive
Zacks Investment Research
1 month ago
Senseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
Seeking Alpha
1 month ago
Senseonics Holdings, Inc. (SENS) Q4 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Rick Sullivan - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Matt Taylor - Jefferies Marie Thibault - BTIG Operator Good day, everyone, and welcome to today's Senseonics Fourth Quarter and Full Year 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Senseonics Holdings, Inc. (SENS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Senseonics Holdings (SENS) Reports Q4 Loss
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
Senseonics Holdings (SENS) Reports Q4 Loss
Neutral
GlobeNewsWire
1 month ago
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Received FDA approval for Eversense ®  365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Neutral
GlobeNewsWire
2 months ago
Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA.
Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
Neutral
GlobeNewsWire
2 months ago
Senseonics Completes CE Mark Submission for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense® 365 CGM system.
Senseonics Completes CE Mark Submission for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
Neutral
GlobeNewsWire
3 months ago
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates.
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
Negative
Zacks Investment Research
5 months ago
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago.
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
Neutral
Seeking Alpha
5 months ago
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Conference Call Participants Brian Langan - Morgan Stanley Vernon Bernardino - H.C. Wainwright Operator Good day, everyone, and welcome to the Senseonics Third Quarter 2024 Earnings Call.
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™